BoneSupport said last week it closed its initial public offering, raising a total of approximately $57.1 million (SEK 500 million), not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it floated approximately 17.2 million new shares at $3.40 per share (SEK 29) in the […]
Orthopedics
BoneSupport readies $62m IPO
BoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece […]
Anika launches late-stage supplemental Cingal study
Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement. The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain. The supplemental late-stage trial is slated to enroll patients at 30 European sites and randomize […]
NovaBone launches bioactive bone graft substitutes
NovaBone Products added NovaBone IRM and IRM MacroPOR to its portfolio of biologically active bone graft substitutes today. The Jacksonville, Fla.-based company touted its devices as the industry’s most advanced bioactive synthetic bone graft substitutes available for orthopedic applications. The 2 new formulations are highly irrigation resistant and promote osteogenesis and osteoblastic activity, according to […]
BoneSupport launches trial of antibiotic-eluting bone graft
BoneSupport said today that the 1st patient has been enrolled in the pivotal investigational device exemption trial for its injectable antibiotic-eluting bone graft substitute. The company’s Fortify trial plans to evaluate Cerament G’s ability to improve the traditional management of patients with open factures of the tibial diaphysis. The trial is slated to enroll up […]
Anika misses Q1 earnings by a penny
Shares in Anika Therapeutics (NSDQ:ANIK) fell today after the orthopedics company missed expectations on Wall Street with its 1st quarter results. The Bedford, Mass.-based company posted profits of $5.5 million, or 37¢ per share, on sales of $23.4 million for the 3 months ended March 31, for bottom-line loss of -20.3% on sales growth of 4.9% compared […]
RepliCel touts tendon regeneration data for its fibroblast therapy
RepliCel Life Sciences (OTC:REPCF) touted data this week from its Phase 1/2 tendon repair study evaluating its type I collagen-expressing, hair follicle-derived fibroblasts as a treatment for Achilles tendinosis. The clinical trial established a complete safety profile for RepliCel’s RCT-01 at 6 months and showed no serious adverse events related to the treatment or injection procedure. […]
Medtech stories we missed this week: March 24, 2017
From companies receiving CE marking to other companies adjusting their distribution deals, here are medtech stories we missed this week but thought were still worth mentioning. 1. Viveve Medical closes public offering Viveve Medical announced that it closed its underwritten public offering of 8,625,00 shares of its common stock, according to a March 22 news release. […]
This new hydrogel can regrow bone in skulls
Researchers in Illinois say they were able to regrow bone to repair a hole in a mouse’s skull. The researchers, based at Northwestern University and the University of Chicago, think their work could lead to significant improvement in the care of people with severe skull or face trauma. They say they were able to regenerate skull bone […]
PolyPid touts early data for BonyPid-1000 antibiotic-eluting bone substitute
PolyPid touted interim data today from the 1st group of patients to reach the 6-month follow-up period in the clinical trial of its BonyPid-1000 doxycycline-eluting synthetic bone substitute. The Israel-based company’s clinical trial enrolled 64 patients with open tibia fractures. In this type of fracture, the bone is severely damaged and exposed, leaving it vulnerable […]